<DOC>
	<DOCNO>NCT01390376</DOCNO>
	<brief_summary>Pharmacotherapy schizophrenia limitation residual positive negative symptom , cognitive deficit intolerable side effect . Refractory schizophrenia ( particularly clozapine-resistant ) still difficult clinical issue present . According N-methyl-D-aspartate ( NMDA ) hypothesis , adjuvant NMDA-enhancing agent may therapeutic benefit . DAAOI-1 , D-amino acid oxidase ( DAAO ) inhibitor , NMDA-enhancing agent . The aim project examine effectiveness safety DAAOI-1 adjuvant treatment clozapine-resistant refractory schizophrenia patient randomize , double-blind , placebo - control trial .</brief_summary>
	<brief_title>DAAOI-1 Treatment Treatment-resistant Schizophrenia</brief_title>
	<detailed_description>Pharmacotherapy schizophrenia limitation residual positive negative symptom , cognitive deficit intolerable side effect . Refractory schizophrenia ( particularly clozapine-resistant ) still difficult clinical issue present . Among schizophrenia patient , around 20-25 % treatment-resistant . According N-methyl-D-aspartate ( NMDA ) hypothesis , many clinical trial NMDA-enhancing agent study . Adjuvant NMDA-enhancing agent , include glycine , D-amino acid ( D-serine , D-alanine ) , sarcosine ( glycine transporter I inhibitor ) , reveal beneficial limited efficacy positive negative symptom . The investigator recently start study potential DAAOI-1 , D-amino acid oxidase ( DAAO ) inhibitor elevate synaptic concentration D-amino acid . The aim project examine effectiveness safety DAAOI-1 adjuvant treatment clozapine-resistant refractory schizophrenia patient randomize , double-blind , placebo - control trial .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Fulfilled DSMIV criterion schizophrenia Poor responder clozapine : 12week treatment without satisfactory response : minimal total score 70 Positive Negative Syndrome Scale ( PANSS ) ( Kay 1987 ) , minimal total score 40 Scale Assessment Negative Symptoms ( SANS ) ( Andreasen 1983 ) . Agree participate study provide informed consent Meet DSMIV criterion AXIS I disorder , current substance dependence mental retardation Serious medical neurological illness Pregnancy lactation Use depot antipsychotic past 6 month Inability follow protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>NMDA</keyword>
	<keyword>DAAOI</keyword>
	<keyword>Clozapine resistant schizophrenia</keyword>
</DOC>